<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158416</url>
  </required_header>
  <id_info>
    <org_study_id>TLXPRO017</org_study_id>
    <nct_id>NCT02158416</nct_id>
  </id_info>
  <brief_title>Platelet Products Tested With the ThromboLUX® Platelet Quality Test</brief_title>
  <official_title>Blinded Study on Consecutive Transfusable Platelet Products Tested With the ThromboLUX® Platelet Quality Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LightIntegra Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LightIntegra Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned minimal risk study is a blinded study on consecutive transfusable platelet&#xD;
      products. The aim of the study is to evaluate the quality of platelet components sampled&#xD;
      prior to transfusion.&#xD;
&#xD;
      The primary patient transfusion outcome in this study is the 1-hour corrected count increment&#xD;
      (1 hr CCI), which is a widely accepted clinical outcome measure. Platelet products will be&#xD;
      sampled for ThromboLUX testing before being sent from the blood bank to the treatment center.&#xD;
      After receipt at the treatment center, the platelet products will be used as per regular&#xD;
      clinical practice, and the outcome data from each patient will be collected. At the end of&#xD;
      the study, TLX Scores will be compared to the transfusion outcomes to determine if a low TLX&#xD;
      Score is associated with a poor transfusion outcome.&#xD;
&#xD;
      During the course of the study, the TLX Score will not be known to the clinicians, or&#xD;
      utilized in any way to decide if the platelet product should be transfused.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TLX Score Correlation with CCI</measure>
    <time_frame>Patients are expected to be enrolled for an average of 6 months.</time_frame>
    <description>The value of the ThromboLUX Score (obtained from platelet products with the ThromboLUX platelet quality test system) to predict patient transfusion outcome (measured as 1hr corrected count increment CCI). The correlation between ThromboLUX score and 1hr CCI (study endpoint) will be reported at the end of the study</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">116</enrollment>
  <condition>Poor Platelet Transfusion Outcome</condition>
  <arm_group>
    <arm_group_label>Hematology-oncology</arm_group_label>
    <description>hematology-oncology outpatients requiring platelet transfusion</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of adults who require treatment of a blood cancer with&#xD;
        platelet transfusion(s). Patients will be stable and thrombocytopenic, however treatment&#xD;
        center will intervene for bleeding. Adult hematology-oncology outpatients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult hematology-oncology outpatients&#xD;
&#xD;
          -  stable and thrombocytopenic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 yrs&#xD;
&#xD;
          -  splenomegaly&#xD;
&#xD;
          -  unable to provide informed consent&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  acute promyelocytic leukemia&#xD;
&#xD;
          -  ITP (Idiopathic thrombocytopenic purpura)&#xD;
&#xD;
          -  HUS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A Heaton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monter Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet</keyword>
  <keyword>transfusion</keyword>
  <keyword>ThromboLUX</keyword>
  <keyword>corrected count increment</keyword>
  <keyword>thrombocytopenic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

